Key facts
- It has raised $12.5M; the latest was Early Stage VC ($12.5M) in May 2025.
- Notable investors include Eshelman Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Paradigm Therapeutics (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Paradigm Therapeutics (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Paradigm Therapeutics (Biotechnology)
Operator of a biopharmaceutical company intended to develop therapies for rare diseases, including Epidermolysis Bullosa. The company is developing a cure for a rare genetic connective tissue disorder that typically manifests at birth or early childhood, enabling patients to get quality treatments.
- Sector
- Healthcare
- HQ
- Mount Pleasant, SC, United States
- Founded
- 2023
- Employees
- 6
- Website
- paradigmtherapeutics.com/
- Ownership
- Privately Held (backing)
Paradigm Therapeutics (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Paradigm Therapeutics (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Paradigm Therapeutics (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.